Welcome to our dedicated page for KIORA PHARMACEUTICALS SEC filings (Ticker: KPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Kiora Pharmaceuticals filings document a clinical-stage ophthalmology issuer focused on small-molecule programs for retinal disease. Current disclosures cover results of operations and financial condition, research-and-development progress for KIO-301 and KIO-104, collaboration reimbursements, and clinical or regulatory updates tied to the company’s development pipeline.
Material-event reports also record securities purchase agreements, common stock, pre-funded warrants and Tranche A warrants issued in private placements, along with executive changes. Proxy materials address board governance, executive compensation, equity awards, shareholder voting matters and related risk-factor disclosures for a Nasdaq-listed Delaware corporation.
Kiora Pharmaceuticals CFO Melissa Tosca reported a small insider transaction involving company common stock. On July 1, 2026, 911 shares were disposed of at $2.66 per share as a tax-withholding disposition, meaning shares were delivered to satisfy tax obligations rather than sold on the open market. Following this transaction, Tosca directly holds 26,064 shares of Kiora Pharmaceuticals common stock.
Kiora Pharmaceuticals' President and CEO Brian M. Strem reported a small share disposition related to taxes. On July 1, 2026, he had 1,869 shares of Kiora common stock transferred at $2.66 per share as a tax-withholding disposition, meaning shares were delivered to cover tax obligations rather than sold on the open market. After this transaction, he directly owns 58,823 common shares, so the adjustment represents a minor change in his overall stake.
Kiora Pharmaceuticals filed a current report describing new preclinical data for its ion channel modulator platform. The company reported that KIO-300, the active ingredient in its Phase 2 vision restoration drug KIO-301, significantly suppressed seizure-associated electrical activity in an ex vivo temporal lobe epilepsy model.
The effect reduced spontaneous epileptiform event frequency versus vehicle controls and remained during treatment and washout, while broader electrical transmission in brain tissue was preserved. These findings, presented at the Epilepsy Foundation Pipeline Conference, support potential applications of KIO-300 in epilepsy and other neurological disorders beyond ophthalmology.
Kiora Pharmaceuticals director Carmine N. Stengone received a stock option grant as part of equity compensation. On June 10, 2026, he was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, with no cash paid for the grant itself.
The options were granted under Kiora’s 2024 Equity Incentive Plan and will become fully exercisable on June 10, 2027. They expire on June 10, 2036 if not exercised. After this award, Stengone holds options for 25,000 underlying shares directly, and the filing does not report any open‑market purchases or sales.
Kiora Pharmaceuticals director Aron Shapiro received a grant of stock options as part of equity compensation. The award covers 25,000 options for Common Stock at an exercise price of $2.63 per share, becomes fully exercisable on June 10, 2027, and expires on June 10, 2036.
Kiora Pharmaceuticals director Erin Parsons reported a compensation-related stock option grant. She received options to buy 25,000 shares of Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and expire on June 10, 2036. After this grant, Parsons holds options covering 25,000 shares. This is an award, not an open-market purchase or sale of stock.
Kiora Pharmaceuticals director David Hollander received a grant of stock options as compensation. He was awarded options covering 25,000 shares of common stock at an exercise price of $2.63 per share, issued under the company’s 2024 Equity Incentive Plan.
The options will become fully exercisable on June 10, 2027 and are scheduled to expire on June 10, 2036 if not exercised. After this grant, Hollander holds 25,000 stock options directly, giving him potential future ownership if the options are exercised.
Kiora Pharmaceuticals director Lisa Walters-Hoffert received a grant of stock options as part of her compensation. She was awarded 25,000 options to buy Kiora common stock at an exercise price of $2.63 per share under the company’s 2024 Equity Incentive Plan.
The options were granted at no cost and relate to 25,000 underlying shares of common stock. They will become fully exercisable on June 10, 2027 and will expire on June 10, 2036 if not exercised. After this grant, she holds 25,000 options directly, and the filing reports no open-market purchases or sales.
Kiora Pharmaceuticals director Praveen Tyle received a grant of stock options as equity compensation. The award covers options on 40,000 shares of common stock at an exercise price of $2.63 per share under the 2024 Equity Incentive Plan.
The options become fully exercisable on June 10, 2027 and expire on June 10, 2036. Following this grant, Tyle holds options on 40,000 shares directly, with no open-market buying or selling reported in this filing.
Kiora Pharmaceuticals, Inc. reported results from its 2026 annual meeting of stockholders. Stockholders approved an amendment to the 2024 Equity Incentive Plan, increasing the shares of common stock authorized for issuance under the plan by 1,500,000 shares.
Three Class II directors — Lisa Walters-Hoffert, Aron Shapiro, and Praveen Tyle, Ph.D. — were re-elected for terms running until the 2029 annual meeting, with over 1,029,000 votes cast for each nominee. Stockholders also approved, on a non-binding advisory basis, the compensation of the company’s named executive officers.
Haskell & White LLP was ratified as independent registered public accounting firm for the fiscal year ending December 31, 2026, receiving 2,358,943 votes for, 5,403 against, and 1,983 abstentions.